©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Feb 27, 2026; 18(2): 114633
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114633
Published online Feb 27, 2026. doi: 10.4240/wjgs.v18.i2.114633
Surgery-assisted transmesenteric transjugular intrahepatic portosystemic shunt for esophagogastric bleeding in patients with cavernous transformation of the portal vein
Si-Ze Wu, Guang-Qing Liu, Department of Ultrasound, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, Hainan Province, China
Author contributions: Wu SZ designed the concept of the manuscript, and critically revised the manuscript; Liu GQ wrote the manuscript. Both authors approved the final version to publish.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Si-Ze Wu, MD, Chief Physician, Professor, Department of Ultrasound, The First Affiliated Hospital of Hainan Medical University, No. 31 Longhua Road, Haikou 570102, Hainan Province, China. wsz074@aliyun.com
Received: September 24, 2025
Revised: November 6, 2025
Accepted: December 3, 2025
Published online: February 27, 2026
Processing time: 155 Days and 2 Hours
Revised: November 6, 2025
Accepted: December 3, 2025
Published online: February 27, 2026
Processing time: 155 Days and 2 Hours
Core Tip
Core Tip: This study suggests that for patients with cavernous transformation of the portal vein and esophagogastric bleeding, surgically assisted transjugular intrahepatic portosystemic shunt offers a survival advantage over endoscopic sclerotherapy at six months, with lower rates of liver failure, rebleeding, and hepatic encephalopathy. However, the surgically assisted transjugular intrahepatic portosystemic shunt carries a risk of serious complications, such as intraoperative hemorrhage and wound infection, which must be weighed against its benefits.